Gossamer Bio (GOSS) Treasury Shares (2018 - 2026)

Gossamer Bio (GOSS) posted quarterly Treasury Shares of $8.2 million for Q1 2026, up 97.51% quarter-over-quarter from $4.1 million in Q4 2025.

Gossamer Bio (GOSS) Treasury Shares (2018 - 2026) Analysis & Trends

Gossamer Bio's Treasury Shares history runs 9 years deep, the most recent figure standing at $8.2 million for Q1 2026.

In Q1 2026, Treasury Shares changed N/A year-over-year to $8.2 million; the TTM figure through Mar 2026 stood at $8.2 million (changed N/A YoY), while the FY2025 annual figure was $4.1 million, changed N/A from the prior year.
Treasury Shares for Q1 2026 stood at $8.2 million, up from $4.1 million in the prior quarter.
The five-year high for Treasury Shares was $8.2 million in Q1 2026, with the low at $8606.0 in Q1 2024.
The 5-year median for Treasury Shares is $1.6 million (2022), against an average of $2.0 million.
The sharpest annual moves came in 2022 and 2024: Treasury Shares sank 37.87% in 2022, then slumped 98.42% in 2024.
Gossamer Bio's Treasury Shares stood at $1.4 million in 2022, then tumbled by 68.32% to $427698.0 in 2023, then tumbled by 97.99% to $8606.0 in 2024, then soared by 47854.47% to $4.1 million in 2025, then surged by 97.51% to $8.2 million in 2026.
Business Quant data shows GOSS's Treasury Shares at $8.2 million in Q1 2026, $4.1 million in Q4 2025, and $2.7 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	36.40 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	8.96 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	2.72 Mn
10	Gossamer Bio	49.15 Mn	-7.87 Mn	-	-

Download Data